title: Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease.
abstract: BACKGROUND
  Excessive use of fructose has been incriminated as a risk factor for hepatic steatosis. Procollagen type III N-terminal peptide (P3NP) is a marker for steatohepatitis. Thus, we aimed to assess fructose intake in obese children and its relation to nonalcoholic fatty liver disease (NAFLD) and P3NP.
  
  
  METHODS
  Fifty-five obese children were compared to 30 controls. All were subjected to dietary fructose and anthropometric assessment, fasting blood sugar (FBS), fasting insulin (FI) and homeostasis model assessment of insulin resistance (HOMA-IR), lipid profile, uric acid, alanine aminotransferase (ALT), P3NP and abdominal ultrasound.
  
  
  RESULTS
  Patients had higher fructose intake which was associated with increased NAFLD grade. There was an increase in P3NP with increased NAFLD grade. P3NP correlated positively with fructose intake (processed sources and total) and caloric intake.
  
  
  CONCLUSIONS
  High fructose intake is associated with NAFLD and P3NP may serve as a marker of NAFLD in obese children with a proposed cutoff value of 8.5 ng/mL.
authors.forename: Rasha Tarif
authors.initials: RT
authors.lastname: Hamza
authors.forename: Alaa Youssef
authors.initials: AY
authors.lastname: Ahmed
authors.forename: Doaa Gamal
authors.initials: DG
authors.lastname: Rezk
authors.forename: Amira Ibrahim
authors.initials: AI
authors.lastname: Hamed
mesh_terms: D000293:Adolescent; D000886:Anthropometry; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D004032:Diet / Q000009:adverse effects*; D002149:Energy Intake; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D009765:Obesity / Q000150:complications*; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D013549:Sweetening Agents / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D011347:Procollagen; D013549:Sweetening Agents; C041876:procollagen Type III-N-terminal peptide; D005632:Fructose